AtriCure to Announce First Quarter 2023 Financial Results

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release first quarter 2023 financial results on Tuesday, May 2, 2023.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, April 11, 2023
Information
Tags: 
Other Consumer, Other Health, Other Science, Research, Medical Devices, Hospitals, Consumer, Genetics, Science, Clinical Trials, Medical Supplies, Cardiology, FDA, Biotechnology, Alternative Medicine, Surgery, Health, Health Technology, Atrial fibrillation, LAA, Liquor, Broadcasting, Online shopping
Geotags: 
OHIO, UNITED STATES, NORTH AMERICA
⚠ partially generated by AI ↴
Organisation: 
ATRICURE, ATRICURE, INC.
Stock Symbol: 
NASDAQ:ATRC
Summary
Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release first quarter 2023 financial results on Tuesday, May 2, 2023.
  • AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 2, 2023, to discuss its first quarter 2023 financial results.
  • Those interested in listening to the conference call should register online using this link .
  • A live and replay version of the audio webcast will be available at https://ir.atricure.com/events-and-presentations/events .


AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release first quarter 2023 financial results on Tuesday, May 2, 2023.

AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 2, 2023, to discuss its first quarter 2023 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricure.com/events-and-presentations/events.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

Copyright: 
Copyright Business Wire 2023